|Mr. David A. Cory R.Ph, MBA||Bus. Founder, Pres, CEO & Director||862.03k||N/A||1964|
|Dr. Jeffrey S. Glenn||Founder, Scientific Advisor & Independent Director||53.5k||N/A||1963|
|Mr. Sriram Ryali M.B.A.||Chief Financial Officer||461.98k||N/A||1981|
|Dr. Stephana E. Patton||Gen. Counsel, Corp. Sec. & Chief Compliance Officer||417.8k||N/A||1971|
|Mr. Eldon C. Mayer III, M.B.A.||Exec. VP & Chief Commercial Officer||55.5k||N/A||1961|
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 9.